Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie’s Disease
- 1 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 203 (6), 1191-1197
- https://doi.org/10.1097/ju.0000000000000743
Abstract
Purpose: To assess the long-term safety and immunogenicity profile of collagenase clostridium histolyticum (CCH) and characterize penile curvature deformity over time in patients previously treated for Peyronie’s disease (PD). Materials and Methods: This phase 4 study included men who received CCH in either 12-month, double-blind, placebo-controlled clinical trials (IMPRESS I/II), or one of two 9-month open-label studies. Eligible patients received no additional CCH treatment and were followed once yearly for up to 5 years to assess PD clinical symptoms, patient-reported outcomes, and safety. Results: Of 280 patients enrolled, 204 (73%) completed the study. At baseline, patients (n=247) had already experienced mean penile curvature decrease from 51.8±15.0° to 31.0±16.1° (improvement of 20.9±16.2° or 39.5%). At Year 5 (n=180), despite no additional treatment, there was an additional 9.1% improvement in mean penile curvature compared with Reference data (4.3±13.4°; 95% CI, 2.3-6.2°; p<0.02). At baseline, patients (n=183) experienced mean Peyronie’s Disease Questionnaire (PDQ) bother domain score improvement from 6.5±3.5 to 3.4±3.3. At Year 5, there was additional score improvement to 2.4±2.9 (p=0.0003). Adverse events (AEs) were reported in 17.5% (49/280) of patients, but no AEs were considered treatment-related. No long-term safety issues were identified up to 5 years posttreatment. Long-term immunogenicity profiling showed a decreasing trend in the number of anti–AUX-I and anti–AUX-II seropositive patients at Years 4 and 5 after CCH treatment. Conclusions: Most CCH-treated patients continued to have penile curvature and PDQ domain score improvements through Year 5 without additional CCH treatment, and no additional safety signals were identified.Keywords
This publication has 13 references indexed in Scilit:
- Understanding the cellular basis and pathophysiology of Peyronie’s disease to optimize treatment for erectile dysfunctionTranslational Andrology and Urology, 2017
- A review of the epidemiology and treatment of Peyronie's diseaseResearch and Reports in Urology, 2016
- Analysis of the clinical safety of intralesional injection of collagenaseClostridium histolyticum(CCH) for adults with Peyronie's disease (PD)BJU International, 2015
- Clinical Safety and Effectiveness of Collagenase Clostridium Histolyticum Injection in Patients with Peyronie’s Disease: A Phase 3 Open-Label StudyThe Journal of Sexual Medicine, 2015
- Bother and Distress Associated with Peyronie's Disease: Validation of the Peyronie’s Disease QuestionnaireJournal of Urology, 2013
- Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 StudiesJournal of Urology, 2013
- The Management of Peyronie’s Disease: Evidence-based 2010 GuidelinesThe Journal of Sexual Medicine, 2010
- Risk Factors for Emotional and Relationship Problems in Peyronie's DiseaseThe Journal of Sexual Medicine, 2008
- The Chronology of Depression and Distress in Men with Peyronie's DiseaseThe Journal of Sexual Medicine, 2008
- Impact of Peyronie's Disease on Sexual and Psychosocial Functioning: Qualitative Findings in Patients and ControlsThe Journal of Sexual Medicine, 2008